|
||
|
 |
|
|
|
|
|
|
|
|
 |
|
|
|
|
 |
 |
 |
 |
 |
 |
|
 |
 |
|
 |
 |
PRESS RELEASE FOR IMMEDIATE RELEASENew Study Finds that Reflective Confocal Microscopy May Be a Feasible Alternative in the Diagnosis of Actinic KeratosesROCHESTER, NEW YORK, USA – May 31, 2007 - A new paper in the May 2007 British Journal of Dermatology reports the results of a new study that found reflective confocal microscopy may be a feasible alternative to skin biopsy in the diagnosis of actinic keratoses against normal skin, as well as in the detection of subclinical forms of this disease. In the paper, titled "Actinic keratoses: non-invasive diagnosis of field cancerisation," the study’s preliminary findings suggest that reflective confocal microscopy (RCM) "may be a useful non-invasive tool for detecting actinic keratoses (AKs)" and that RCM "may be a feasible alternative to clinical diagnosis alone and could aid in the differentiation of AKs against normal skin, as well as in the detection of subclinical disease." "In the context of ‘field cancerisation’," the paper states, "repeated and multiple biopsies may not always be considered a practical approach. Therefore, evidence suggests that RCM may be a promising tool for the non-invasive evaluation, diagnosis and monitoring of AKs." For the in vivo RCM evaluation, a Vivascope® 1500, manufactured by Lucid Inc. of Rochester, NY (www.lucid-tech.com), was used to image AKs and the respective control skin sites. "The VivaScope® 1500 potentially provides an alternative to routine skin biopsy in many clinical situations," said Jay Eastman, chairman and CEO of Lucid, Inc. "With the publication of this new study, the potential effectiveness of Vivascope technology has been shown for actinic keratoses, a precursor to squamous cell carcinoma. "Lucid VivaScope imagers are being used in a number of leading medical institutions in the US and in Europe. We expect that the publication of this most recent successful study will further accelerate the growing acceptance of VivaScope® technology by clinical institutions and private practices alike," Eastman said. "Just as MRI and CT scans provide a rapid and non-invasive means to image the gross anatomical structures of the body, VivaScope® technology provides rapid, non-invasive in-vivo images showing cellular morphology and nuclear detail. This potentially permits pathologic diagnosis without the need to excise tissue," he said. Study Abstract Actinic keratoses (AKs) are among the most common cutaneous malignancies and have previously been classified as in situ squamous cell carcinoma (SCC) with reported progression rates of up to 20% over 10 years. Since current scientific evidence suggests the presence of multilocular preneoplastic changes in the areas surrounding the affected skin sites, the detection of subclinical AKs remain an ongoing and challenging effort in the clinical and diagnostic management of these lesions. In vivo rRCM has been used for evaluation of the morphological features of non-melanoma skin cancer (NMSC) and RCM evaluation parameters for the diagnosis of AKs have been reported. The objective of the study was to evaluate the RCM-morphology of clinically diagnosed AKs in our study population and to correlate the findings with routine histopathology. Forty four Caucasians (SPT I-III) with a minimum of one actinic keratosis (AK) lesion were included in this study. Evaluation consisted of clinical examination, RCM and routine histology. Reflectance confocal microscopy evaluation parameters included parakeratosis, architectural disarray and keratinocyte pleomorphism. A total of 44 AKs were included in the final analysis. Following blinded evaluation by two independent investigators, 97·7% of all skin samples were identified as AK using RCM. 2·3% were incorrectly identified as normal skin by RCM, while routine histology showed features consistent with AK. For the entire article, see the British Journal of Dermatology, Volume 156 s3, May 2007, pp 13-17, "Actinic keratoses: non-invasive diagnosis for field cancerisation," authors: M. Ulrich, A. Maltusch, J. Röwert-Huber, S. González, W. Sterry, E. Stockfleth, S. Astner. Or, on the Web, visit here. M. Ulrich, A. Maltusch, J. Röwert-Huber, W. Sterry, E. Stockfleth and S. Astner are of the Department of Dermatology, Charité, Skin Cancer Center Charité, University Hospital of Berlin, Berlin, Germany. S. González is of the Dermatology Service, Hospital Ramon y Cajal, Madrid, Spain and the Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. About Lucid Inc. Lucid Inc., based in Rochester, New York, USA, is a medical device and information company dedicated to creating innovative cellular imaging technology and using the Internet to securely deliver accurate, real-time VivaScope® cellular resolution images to medical professionals. When coupled with its digital VivaNetTM system, the company’s ability to image in-vivo (living) tissue will aid medical practitioners and pathologists in skin cancer screening with clarity, speed and patient comfort. For more information about Lucid Inc., visit www.Lucid-tech.com. Note to Editors: Press contacts: |
|
© Copyright Lucid, Inc. All rights reserved. Site designed by Tiziani Whitmyre, Inc. |
||